Analyst: Novo Nordisk was expected to complete acquisition – despite issues
Though there was trouble along the way, it was no surprise that Novo Nordisk managed to close the billion-dollar acquisition of Dicerna Pharmaceuticals, says an analyst at Sydbank.
by marketwire, translated by daniel pedersen
On Tuesday, bets that Novo Nordisk would indeed cross the finish line of the reported USD 3.3bn acquisition of Dicerna Pharmaceuticals could finally be cashed out.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
.jpg)
Novo Nordisk closes Dicerna acquisition deal
For subscribers
